C
에임드바이오
0009K0KOSDAQ45.0 / 100
Reference Date: 2026-10-23
Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 5.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
AimedBio is a global biotech company specializing in the development of antibody-drug conjugate (ADC)-based anticancer therapeutics, leveraging patient-derived models and proprietary linker-payload technology. As a spin-off from Samsung Seoul Hospital, the company has achieved milestones through technology transfers and co-development agreements with global pharmaceutical firms since 2024.
Number of Employees
52people
Average Salary
69.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
198.15Industry Average 15.000.0Point
13.2x industry avg (risky)
PBR
7.24Industry Average 1.200.0Point
6.0x industry avg (risky)
ROE
5.12Industry Average 8.002.5Point
Below industry avg
Debt Ratio
0.37Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 6.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
3.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (6%, downtrend)
Current 21,400Won52-week high 72,50052-week low 17,900
1-month return2.0Point
1m -5.31% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0